| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B: A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Aug 28;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17761356 (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| |
| http://linked.open...ugbank/indication
| - For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Minoxidil is thought to promote the survival of human dermal papillary cells (DPCs) or hair cells by activating both extracellular signal-regulated kinase (ERK) and Akt and by preventing cell death by increasing the ratio of BCl<sup>-</sup>2/Bax. Minoxidil may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects on DPCs. Minoxidil, when used as a vasodilator, acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. This vasodilation may also improve the viability of hair cells or hair follicles. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...y/drugbank/patent
| |
| http://linked.open.../drugbank/synonym
| - Minoxidil (en)
- Alostil (en)
- Loniten (en)
- Lonolox (en)
- Minoximen (en)
- Normoxidil (en)
- Regaine (en)
- Rogaine (en)
- Tricoxidil (en)
- 2,4-Diamino-6-piperidinopyrimidine 3-oxide (en)
- 6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide (en)
- Apo-gain (en)
- Minossidile (en)
- Minoxidilum (en)
|
| http://linked.open...drugbank/toxicity
| - Oral LD<sub>50</sub> in rats has ranged from 1321-3492 mg/kg; in mice, 2456-2648 mg/kg. Side effects include cardiovascular effects associated with hypotension such as sudden weight gain, rapid heart beat, faintness or dizziness. (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open...k/foodInteraction
| - Take without regard to meals. (en)
|
| http://linked.open...nk/proteinBinding
| - Minoxidil does not bind to plasma proteins. (en)
|
| http://linked.open...ynthesisReference
| - Paul S. Uster, Yolanda P. Quinn, "Non-crystalline minoxidil composition, its production and application." U.S. Patent US4828837, issued March, 1985. (en)
|
| foaf:page
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)